Cerenome (CNSY)
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer....
- Open
- 3.040
- High
- 3.115
- Low
- 2.970
- Prev. Close
- 3.000
- Volume
- 106.24K
- Turnover
- 322.77K
- Avg Price
- 3.038
- Bid/Ask Ratio
- --
- Amplitude
- 4.83%
- 52wk High
- 23.425
- Volume Ratio
- 0.00
- Turnover Ratio
- 1.65%
Cerenome Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$36.001072.64%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Aug 18 at 05:12 AM
The Market's Junk Drawer: AI Grifters, Nuclear Leverage, and SPACs Refusing to Die
- Earnings Watch · Aug 15 at 12:41 AM
Cerenome | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 411 K
- Unusual Whales · Aug 14 at 03:17 PM
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
- PUBT · Aug 14 at 03:16 PM
Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 million
- Global Report · Aug 5 at 04:13 AM
Capital Rotation Beyond Mega-Caps: Institutional Flows Target Supply Chains and Sports Franchises
- PUBT · Aug 4 at 04:34 PM
Plus Therapeutics amends bylaws to reflect corporate name change to Cerenome
